Literature DB >> 12938169

Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG).

Kourosh Sarkhosh1, Edward E Tredget, Ali Karami, Hasan Uludag, Takashi Iwashina, Ruhangiz T Kilani, Aziz Ghahary.   

Abstract

Indoleamine 2,3-dioxygenase (IDO), a tryptophan-catabolizing enzyme, is an intracellular enzyme possessing various immunosuppressive properties. Here, we report the possible use of this enzyme to suppress proliferation of immune cells cocultured with IDO-expressing fibroblasts of an allogenic skin substitute. Fetal skin fibroblasts embedded within bovine collagen were treated with cytokine interferon-gamma (IFN-gamma) to induce expression of IDO mRNA and protein. Expression of IDO mRNA was evaluated by Northern analysis. IDO enzyme activity was evaluated by measurement of kynurenine and tryptophan levels in the IFN-gamma untreated and treated fibroblasts. The results of Northern analysis showed a dose-dependent increase in expression of IDO mRNA in response to various concentrations of IFN-gamma used. The levels of kynurenine and tryptophan measured, as the bioactivity of IDO, were significantly different in the IFN-gamma treated fibroblasts, compared to those of controls (P < 0.001). In a lasting effect experiment, the expression of IDO mRNA was gradually reduced to an undetectable level within 32 h of IFN-gamma removal. The results of Western blot analysis, however, revealed a significantly longer (192 h) lasting effect of IFN-gamma on IDO protein level, relative to that of mRNA expression. To demonstrate immunosuppressive effects of IDO on proliferation of immune cells, IDO-expressing fibroblasts were cocultured with peripheral blood mononuclear cells (PBMC) for a period of 5 days. The results of (3)H-thymidine incorporation showed a significant reduction in proliferation of PBMC when cocultured with IDO-expressing fibroblasts, compared to those cocultured with non-IDO-expressing fibroblasts (P < 0.001). Furthermore, addition of IDO-inhibitor (1-methyl-d-tryptophan) reversed the suppressive effects of IDO on PBMC proliferation in a dose-dependant fashion. To test the viability of immune cells cocultured with IDO-expressing fibroblasts, FACS analysis of the PI stained PBMC was conducted and no significant difference was found between these cells and the controls. In another set of experiments, we showed that migration rate and subsequent proliferation of IDO-expressing fibroblasts are also the same as those of control cells. In conclusion, IDO-expressing allogenic fibroblasts embedded within collagen gel suppress the proliferation of allogenic immune cells, while they still remain viable in this IDO-induced tryptophan-deficient culture environment. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938169     DOI: 10.1002/jcb.10593

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  11 in total

Review 1.  Tryptophan metabolites kynurenine and serotonin regulate fibroblast activation and fibrosis.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

2.  Human fibroblasts share immunosuppressive properties with bone marrow mesenchymal stem cells.

Authors:  Sandrine Cappellesso-Fleury; Bénédicte Puissant-Lubrano; Pol-André Apoil; Matthias Titeux; Peter Winterton; Louis Casteilla; Philippe Bourin; Antoine Blancher
Journal:  J Clin Immunol       Date:  2010-04-20       Impact factor: 8.317

3.  Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis.

Authors:  S B Adikari; H Lian; H Link; Y-M Huang; B-G Xiao
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

4.  Mouse pancreatic islets are resistant to indoleamine 2,3 dioxygenase-induced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function.

Authors:  Reza B Jalili; Farshad Forouzandeh; Alireza Moeenrezakhanlou; Gina R Rayat; Ray V Rajotte; Hasan Uludag; Aziz Ghahary
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

5.  The molecular mechanism of hypertrophic scar.

Authors:  Zhensen Zhu; Jie Ding; Heather A Shankowsky; Edward E Tredget
Journal:  J Cell Commun Signal       Date:  2013-03-18       Impact factor: 5.782

6.  Mechanism underlying defective interferon gamma-induced IDO expression in non-obese diabetic mouse fibroblasts.

Authors:  Azadeh Hosseini-Tabatabaei; Reza Baradar Jalili; Yunyuan Li; Ruhangiz T Kilani; Alireza Moeen Rezakhanlou; Aziz Ghahary
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

7.  Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential.

Authors:  Antonella Blasi; Carmela Martino; Luigi Balducci; Marilisa Saldarelli; Antonio Soleti; Stefania E Navone; Laura Canzi; Silvia Cristini; Gloria Invernici; Eugenio A Parati; Giulio Alessandri
Journal:  Vasc Cell       Date:  2011-02-08

8.  Local expression of indoleamine 2,3 dioxygenase in syngeneic fibroblasts significantly prolongs survival of an engineered three-dimensional islet allograft.

Authors:  Reza B Jalili; Farshad Forouzandeh; Alireza Moeen Rezakhanlou; Ryan Hartwell; Abelardo Medina; Garth L Warnock; Bagher Larijani; Aziz Ghahary
Journal:  Diabetes       Date:  2010-06-03       Impact factor: 9.461

9.  Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.

Authors:  Edwin B Yan; Tony Frugier; Chai K Lim; Benjamin Heng; Gayathri Sundaram; May Tan; Jeffrey V Rosenfeld; David W Walker; Gilles J Guillemin; Maria Cristina Morganti-Kossmann
Journal:  J Neuroinflammation       Date:  2015-05-30       Impact factor: 8.322

10.  A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage.

Authors:  Colette Dezutter-Dambuyant; Isabelle Durand; Laurent Alberti; Nathalie Bendriss-Vermare; Jenny Valladeau-Guilemond; Adeline Duc; Audrey Magron; Anne-Pierre Morel; Vanja Sisirak; Céline Rodriguez; David Cox; Daniel Olive; Christophe Caux
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.